BIGBEAR
PHARMACEUTICAL
Osimertinib is a third-generation targeted therapy for lung cancer, specifically designed to treat non-small cell lung cancer driven by specific genetic mutations.
AuthenticGuaranteeFast DeliveryPrivacy Osimertinib Pharmacokinetics1. Absorption(1) Peak plasma concentration reached approximately 6 hours (range 3–24 hours) after oral administration.(2) ···【More】
Update: 14 Jul,2026Source: BigbearViews: 95
Osimertinib Common Adverse Reactions1. Adverse Reactions with Monotherapy (>20%)Leukopenia, lymphopenia, anemia, diarrhea, rash, musculoskeletal pa···【More】
Update: 14 Jul,2026Source: BigbearViews: 100
Osimertinib Precautions1.Interstitial Lung Disease/PneumonitisSevere or fatal interstitial lung disease (ILD) or pneumonitis may occur.(1).For patient···【More】
Update: 14 Jul,2026Source: BigbearViews: 97
Osimertinib is a targeted therapy for EGFR-mutant non-small cell lung cancer. During treatment, close monitoring is required for interstitial lung dis···【More】
Update: 14 Jul,2026Source: BigbearViews: 98
During treatment with Osimertinib, various side effects may occur. If you are unable to determine whether the side effects are serious, please consult···【More】
Update: 10 Jul,2026Source: BigbearViews: 104
Osimertinib Use in Special Populations1. Renal Impairment(1) Patients with creatinine clearance (CrCl) between 15 and 89 mL/min: no dose adjustment is···【More】
Update: 10 Jul,2026Source: BigbearViews: 112
Osimertinib is commonly used for non-small cell lung cancer (NSCLC). The recommended dose is 80 mg once daily. As individual circumstances vary, the u···【More】
Update: 10 Jul,2026Source: BigbearViews: 110
On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to an oral medication for the treatment of patients wit···【More】
Update: 08 May,2026Source: BigbearViews: 173
March 31, 2017 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Osimertinib (brand name: Tagrisso···【More】
Update: 08 May,2026Source: BigbearViews: 137
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved the targeted therapy Osimertinib for the first-···【More】
Update: 07 May,2026Source: BigbearViews: 133
Osimertinib is a tyrosine kinase inhibitor used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have been identified—via an FDA···【More】
Update: 07 May,2026Source: BigbearViews: 135
On December 21, 2020, AstraZeneca’s Osimertinib was approved in the United States for the adjuvant treatment of adult patients with early-stage epider···【More】
Update: 07 May,2026Source: BigbearViews: 124
On February 19, 2024, AstraZeneca announced that its drug, osimertinib, has received approval in the United States for use in combination with chemoth···【More】
Update: 07 May,2026Source: BigbearViews: 129
September 26, 2024, Cambridge, UK — AstraZeneca’s osimertinib has received approval in the United States for the treatment of adult patients with unre···【More】
Update: 07 May,2026Source: BigbearViews: 130
Osimertinib is indicated for the treatment of various types of non-small cell lung cancer (NSCLC). Before initiating treatment, an FDA-approved diagno···【More】
Update: 06 Mar,2026Source: BigbearViews: 147
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
